CA3195023A1 - Treatment of nsclc patients with tumor infiltrating lymphocyte therapies - Google Patents
Treatment of nsclc patients with tumor infiltrating lymphocyte therapiesInfo
- Publication number
- CA3195023A1 CA3195023A1 CA3195023A CA3195023A CA3195023A1 CA 3195023 A1 CA3195023 A1 CA 3195023A1 CA 3195023 A CA3195023 A CA 3195023A CA 3195023 A CA3195023 A CA 3195023A CA 3195023 A1 CA3195023 A1 CA 3195023A1
- Authority
- CA
- Canada
- Prior art keywords
- tils
- population
- inhibitor
- days
- expansion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063127027P | 2020-12-17 | 2020-12-17 | |
| US63/127,027 | 2020-12-17 | ||
| US202163146402P | 2021-02-05 | 2021-02-05 | |
| US63/146,402 | 2021-02-05 | ||
| USPCT/US2021/053841 | 2021-10-06 | ||
| PCT/US2021/053841 WO2022076606A1 (en) | 2020-10-06 | 2021-10-06 | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| PCT/US2021/055304 WO2022076952A1 (en) | 2020-10-06 | 2021-10-15 | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3195023A1 true CA3195023A1 (en) | 2022-04-14 |
Family
ID=86282189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3195023A Pending CA3195023A1 (en) | 2020-12-17 | 2021-10-15 | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP2023544199A (enExample) |
| CA (1) | CA3195023A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115927303A (zh) * | 2022-07-13 | 2023-04-07 | 南京鼓楼医院 | TBL1XR1基因及其gRNA在制备提升T细胞功能药物中的应用 |
| CN115944650A (zh) * | 2023-01-03 | 2023-04-11 | 青岛大学 | 肿瘤浸润细胞在制备抗肿瘤药物中的应用及模型构建方法 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023546359A (ja) * | 2020-10-06 | 2023-11-02 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202031273A (zh) * | 2018-08-31 | 2020-09-01 | 美商艾歐凡斯生物治療公司 | 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療 |
-
2021
- 2021-10-15 CA CA3195023A patent/CA3195023A1/en active Pending
- 2021-10-15 JP JP2023521067A patent/JP2023544199A/ja active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115927303A (zh) * | 2022-07-13 | 2023-04-07 | 南京鼓楼医院 | TBL1XR1基因及其gRNA在制备提升T细胞功能药物中的应用 |
| CN115944650A (zh) * | 2023-01-03 | 2023-04-11 | 青岛大学 | 肿瘤浸润细胞在制备抗肿瘤药物中的应用及模型构建方法 |
| CN115944650B (zh) * | 2023-01-03 | 2023-11-28 | 青岛大学 | 肿瘤浸润细胞在制备抗肿瘤药物中的应用及模型构建方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023544199A (ja) | 2023-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240131064A1 (en) | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors | |
| US12611427B2 (en) | Treatment of NSCLC patients refractory for anti-PD-1 antibody | |
| US12553029B2 (en) | Treatment of NSCLC patients with tumor infiltrating lymphocyte therapies | |
| US20240342285A1 (en) | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors | |
| US20240325446A1 (en) | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors | |
| AU2022263418A1 (en) | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies | |
| US20240123067A1 (en) | Treatment of cancers with tumor infiltrating lymphocyte therapies | |
| WO2022076606A1 (en) | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies | |
| CA3248034A1 (en) | METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT | |
| CA3195023A1 (en) | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies | |
| US20240424097A1 (en) | Processes for generating til products using pd-1 talen knockdown | |
| EP4504220A1 (en) | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies | |
| WO2024030758A1 (en) | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies | |
| US20250032618A1 (en) | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes | |
| US20250000903A1 (en) | Expansion processes and agents for tumor infiltrating lymphocytes | |
| US20250281537A1 (en) | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist | |
| US20240365776A1 (en) | Method for cryopreservation of solid tumor fragments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241011 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241011 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250924 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250924 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20251010 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20251010 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251010 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251211 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251211 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251211 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251211 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20251212 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251217 |